Breast Cancer | China In-Depth | China | 2024
The breast cancer therapy market is one of the most dynamic markets in the oncology space in mainland China. Several new and emerging therapies are set to be approved for select subpopulations; although these approvals will increase sales during the 2023-2033 forecast period, intense competition between agents in key treatable populations will limit individual therapies’ potential. Although price erosion is likely to be less aggressive with biosimilars than with small-molecule drugs, the substantial use of trastuzumab and pertuzumab biosimilars, particularly in the early-stage and first-line metastatic settings, will dampen overall sales. In this report, we assess how clinical and nonclinical factors—price dynamics, inclusion in the NRDL—will influence the launch and uptake of new therapies in this market. Understanding the impact of these intersecting factors will be key to the success of current and future players in this burgeoning market.
QUESTIONS ANSWERED
- How large is China’s drug-treatable breast cancer population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s breast cancer market, and why?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of breast cancer in China?
- What are the key market access considerations, and how will they impact the uptake of emerging therapies for breast cancer in China?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Release date
June 2024
Geography
China
Primary research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 medical oncologists.
Epidemiology
Diagnosed incidence of breast cancer in China, with urban and rural breakup. Clinically and market-relevant drug-treatable populations.
Forecast
10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase 3 / PR: 10+ drugs; Phase 2: 10+ drugs; coverage of select preclinical and Phase 1 products
NEW: China In-Depth reports include a custom drug modeler. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate’s projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.
